Tokyo University Confirms Efficacy Of Existing Drug For Hereditary Liver Disease In Children
This article was originally published in PharmAsia News
A Tokyo University team has confirmed in clinical studies the efficacy of a drug in the treatment of a hereditary liver disease occurring in children, progressive familial intrahepatic cholestasis type 2.
You may also be interested in...
Despite so many COVID-19 uncertainties, e.l.f. Beauty has the confidence of a company that posted 6% net sales growth to $283m for the 2020 fiscal year ended on 31 March and is seeing its value proposition for "prestige-quality" cosmetics resonate even more powerfully with consumers in today’s volatile economic climate.
Latest warning to Humaworm notes findings that FDA inspectors made in July 2019. FDA officials apparently have been in Humaworm’s facility since then, executing a search warrant in October and confiscating encapsulating machines, herbs, capsules, computers, and records.
After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.